TE · Investment summary · as of 4 August 2026
Priced for an operating path the record does not support
Business type: Cyclical · venture-like, not yet economically observable
The operating path required by today's price is not achievable on the evidence.
At $4.95, the gap between what the price requires and what the business has demonstrated is -21.1 percentage points.
The disagreement with the market is not about growth. T1 is growing +88.3% YoY on a same-perimeter basis (Q2-2026 preliminary vs Q2-2025) and +232.3% (Q1-2026 vs Q1-2025); no plausible required growth rate is the binding question.
The value rests on an exit multiple of 9.6x and a 11.2% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is not about growth. |
| What do we forecast? | An exit multiple of 9.6x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -21.1 percentage points. |
| What is it worth? | Twelve-month target $5.80, +17% from the struck price. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| every 10-Q and 10-K through Q4-2027 | Third-party (non-Trina-Group) revenue does not reach 15% of total net… | Neither leg of the condition opposite is met at this date | Third-party (non-Trina-Group) revenue does not reach 15% of total net sales in any reported quarter through Q4-2027. |
| two consecutive quarters, Q3-2026 and Q4-2026 | Product gross margin excluding Section 45X — reported gross profit… | Neither leg of the condition opposite is met at this date | Product gross margin excluding Section 45X |
| quarterly | Realised Section 45X credits fall below $0.05/W (against the $0.07/W… | Realised Section 45X credits fall at or above $0.05/W (against the $0.07/W T1 states it expects to qualify for), or a… | Realised Section 45X credits fall below $0.05/W (against the $0.07/W T1 states it expects to qualify for), or a… |
Not determined — the permanent-loss case could not be published in full without internal detail
Falsifiable and fundamental — not one of them is a price condition.
Not applicable — no position may be opened. On approach to the $5.80 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | What is the realistic permanent-loss case? |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -21.1 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $3.71, which forces an immediate review.